ReviewMethodist DeBakey cardiovascular journal
Update on Management of Type 2 Diabetes for Cardiologists.
Review in Methodist DeBakey cardiovascular journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From toxicogenomics data to cumulative assessment groups: a framework for chemical grouping.Archives of toxicology · 2026Article
- Inhibiting Glucose Metabolism By miR-34a and miR-125b Protects Against Hyperglycemia-Induced Cardiomyocyte Cell Death.Arquivos brasileiros de cardiologia · 2021Article
- Predicting complications of diabetes mellitus using advanced machine learning algorithms.Journal of the American Medical Informatics Association : JAMIA · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of type 2 diabetes mellitus has evolved over the last several years as new antidiabetic agents continue to arrive and change the goals of diabetes care. In 2008, the U.S. Food and Drug Administration mandated that all new antidiabetic agents must demonstrate cardiovascular (CV) safety, which has led to a series of CV outcome trials. In this article, we review the key findings from these CV outcome trials and their impact on diabetes care guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.